J&J Loses Louisiana Appeal of Risperdal Fraud Jury Verdict

J&J Loses Louisiana Appeal of Risperdal Fraud Jury Verdict

JB Reed/Bloomberg News.

In the Louisiana case, lawyers argued Johnson & Johnson and its Janssen unit defrauded the state’s Medicaid program by wrongfully marketing the schizophrenia drug Risperdal to doctors as safer and better than competing medicines so they could sell it at an artificially inflated price.